SubHero Banner

Cinvanti® (aprepitant) – Expanded indication

October 22, 2019 - Heron Therapeutics announced the FDA approval of Cinvanti (aprepitant), in combination with other antiemetic agents in adult patients for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen.

Download PDF